Ohr presents additional positive study data

Ohr Pharmaceutical Inc. (Nasdaq: OHRP) presented additional positive data from the IMPACT study interim analysis at the 38th Annual Macula Society Meeting. The stock price leaped $2.09 to close at $9.78.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.